MAPK8 and hepatocellular carcinoma: By contrast, PARP14 promotes the development of HCC by inhibiting c-Jun N-terminal kinase 1 (JNK1), which phosphorylates and activates pyruvate kinase M2 (PKM2), thus maintaining low activity of PKM2 and promoting aerobic glycolysis in HCC (74).